Loading...

We've got a brand new version of Simply Wall St! Try it out

Cardlytics

Nasdaq:CDLX
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CDLX
Nasdaq
$1B
Market Cap
  1. Home
  2. US
  3. Media
Company description

Cardlytics, Inc. operates a purchase intelligence platform in the United States and the United Kingdom. The last earnings update was 2 days ago. More info.


Add to Portfolio Compare Print
  • Cardlytics has significant price volatility in the past 3 months.
CDLX Share Price and Events
7 Day Returns
42.4%
NasdaqGM:CDLX
2%
US Media
0.5%
US Market
1 Year Returns
316.8%
NasdaqGM:CDLX
17.6%
US Media
12.8%
US Market
CDLX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Cardlytics (CDLX) 42.4% 48.9% 67.6% 316.8% - -
US Media 2% 4.5% 10% 17.6% 24.9% 33%
US Market 0.5% 4.3% 8% 12.8% 38.7% 44.5%
1 Year Return vs Industry and Market
  • CDLX outperformed the Media industry which returned 17.6% over the past year.
  • CDLX outperformed the Market in United States of America which returned 12.8% over the past year.
Price Volatility
Industry
5yr Volatility vs Market

CDLX Value

 Is Cardlytics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Cardlytics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Cardlytics.

NasdaqGM:CDLX Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 7 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.8%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:CDLX
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Media Unlevered Beta Simply Wall St/ S&P Global 0.78
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.775 (1 + (1- 21%) (0%))
0.849
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.85
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.849 * 5.96%)
7.79%

Discounted Cash Flow Calculation for NasdaqGM:CDLX using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Cardlytics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

NasdaqGM:CDLX DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.79%)
2020 -12.81 Analyst x2 -11.88
2021 8.00 Analyst x1 6.89
2022 11.30 Est @ 41.22% 9.02
2023 14.65 Est @ 29.67% 10.85
2024 17.81 Est @ 21.59% 12.24
2025 20.65 Est @ 15.93% 13.16
2026 23.12 Est @ 11.97% 13.67
2027 25.25 Est @ 9.2% 13.85
2028 27.08 Est @ 7.26% 13.78
2029 28.68 Est @ 5.9% 13.54
Present value of next 10 years cash flows $95.00
NasdaqGM:CDLX DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $28.68 × (1 + 2.73%) ÷ (7.79% – 2.73%)
$581.92
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $581.92 ÷ (1 + 7.79%)10
$274.77
NasdaqGM:CDLX Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $95.00 + $274.77
$369.77
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $369.77 / 25.71
$14.38
NasdaqGM:CDLX Discount to Share Price
Calculation Result
Value per share (USD) From above. $14.38
Current discount Discount to share price of $56.94
= -1 x ($56.94 - $14.38) / $14.38
-295.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Cardlytics is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Cardlytics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Cardlytics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:CDLX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $-1.42
NasdaqGM:CDLX Share Price ** NasdaqGM (2019-11-13) in USD $56.94
United States of America Media Industry PE Ratio Median Figure of 38 Publicly-Listed Media Companies 13.32x
United States of America Market PE Ratio Median Figure of 2,922 Publicly-Listed Companies 18.24x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Cardlytics.

NasdaqGM:CDLX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:CDLX Share Price ÷ EPS (both in USD)

= 56.94 ÷ -1.42

-40.13x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cardlytics is loss making, we can't compare its value to the US Media industry average.
  • Cardlytics is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Cardlytics's expected growth come at a high price?
Raw Data
NasdaqGM:CDLX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -40.13x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
72.4%per year
United States of America Media Industry PEG Ratio Median Figure of 29 Publicly-Listed Media Companies 1.38x
United States of America Market PEG Ratio Median Figure of 2,023 Publicly-Listed Companies 1.46x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Cardlytics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Cardlytics's assets?
Raw Data
NasdaqGM:CDLX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $4.96
NasdaqGM:CDLX Share Price * NasdaqGM (2019-11-13) in USD $56.94
United States of America Media Industry PB Ratio Median Figure of 73 Publicly-Listed Media Companies 1.37x
United States of America Market PB Ratio Median Figure of 5,070 Publicly-Listed Companies 1.73x
NasdaqGM:CDLX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:CDLX Share Price ÷ Book Value per Share (both in USD)

= 56.94 ÷ 4.96

11.48x

* Primary Listing of Cardlytics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Cardlytics is overvalued based on assets compared to the US Media industry average.
X
Value checks
We assess Cardlytics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Media industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Media industry average (and greater than 0)? (1 check)
  5. Cardlytics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CDLX Future Performance

 How is Cardlytics expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
72.4%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Cardlytics expected to grow at an attractive rate?
  • Cardlytics's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Cardlytics's earnings growth is expected to exceed the United States of America market average.
  • Cardlytics's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:CDLX Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:CDLX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 72.4%
NasdaqGM:CDLX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 24.5%
United States of America Media Industry Earnings Growth Rate Market Cap Weighted Average 18.4%
United States of America Media Industry Revenue Growth Rate Market Cap Weighted Average 3.6%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.3%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:CDLX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:CDLX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 523 99 44 2
2022-12-31 436 72 20 2
2021-12-31 347 31 6 4
2020-12-31 261 7 -14 7
2019-12-31 201 6 -28 5
2019-11-14
NasdaqGM:CDLX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 189 3 -32
2019-06-30 167 -9 -33
2019-03-31 154 -20 -39
2018-12-31 151 -19 -53
2018-09-30 142 -20 -46
2018-06-30 139 -29 -41
2018-03-31 136 -16 -33
2017-12-31 130 -22 -25
2017-09-30 128 -19 -28
2017-06-30 127 -16 -51
2017-03-31 120 -26 -77
2016-12-31 113 -32 -77

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Cardlytics's earnings are expected to grow significantly at over 20% yearly.
  • Cardlytics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:CDLX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Cardlytics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:CDLX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.92 1.92 1.92 1.00
2022-12-31 0.88 0.88 0.88 1.00
2021-12-31 0.23 0.64 -0.04 4.00
2020-12-31 -0.61 -0.25 -0.90 7.00
2019-12-31 -1.15 -1.02 -1.26 4.00
2019-11-14
NasdaqGM:CDLX Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 -1.42
2019-06-30 -1.49
2019-03-31 -1.84
2018-12-31 -2.79
2018-09-30 -3.18
2018-06-30 -4.00
2018-03-31 -5.63
2017-12-31 -7.86
2017-09-30 -9.42
2017-06-30 -18.43
2017-03-31 -31.04
2016-12-31 -32.48

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Cardlytics is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Cardlytics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Cardlytics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CDLX Past Performance

  How has Cardlytics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Cardlytics's growth in the last year to its industry (Media).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Cardlytics does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Cardlytics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Cardlytics's 1-year growth to the US Media industry average as it is not currently profitable.
Earnings and Revenue History
Cardlytics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Cardlytics Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:CDLX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 188.96 -32.14 83.72 12.51
2019-06-30 167.12 -32.76 77.81 13.59
2019-03-31 153.96 -39.30 77.65 15.69
2018-12-31 150.68 -53.20 76.11 16.21
2018-09-30 142.13 -46.05 65.24 15.07
2018-06-30 138.96 -40.51 61.44 14.39
2018-03-31 136.20 -32.89 54.90 12.60
2017-12-31 130.37 -25.38 52.03 12.15
2017-09-30 127.52 -28.25 51.71 12.33
2017-06-30 127.28 -50.78 50.27 12.13
2017-03-31 120.36 -77.22 51.15 12.26
2016-12-31 112.82 -76.68 51.97 13.35
2015-12-31 77.63 -41.63 50.98 11.60

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Cardlytics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Cardlytics has efficiently used its assets last year compared to the US Media industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Cardlytics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Cardlytics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Media industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Cardlytics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CDLX Health

 How is Cardlytics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Cardlytics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Cardlytics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Cardlytics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Cardlytics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are -33215x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Cardlytics Company Filings, last reported 1 month ago.

NasdaqGM:CDLX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 127.32 0.04 95.18
2019-06-30 46.54 36.66 32.50
2019-03-31 47.18 46.66 36.43
2018-12-31 51.98 46.66 39.62
2018-09-30 51.23 46.75 47.81
2018-06-30 36.77 47.45 50.47
2018-03-31 40.56 58.48 89.79
2017-12-31 -9.96 56.91 21.26
2017-09-30 -7.09 55.39 28.19
2017-06-30 -5.55 53.90 40.34
2017-03-31 -79.62 124.18 24.35
2016-12-31 -68.62 111.70 22.84
2015-12-31 0.84 31.85 27.32
  • Cardlytics's level of debt (-0%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Cardlytics's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Cardlytics has sufficient cash runway for more than 3 years based on current free cash flow.
  • Unable to confirm if Cardlytics has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Cardlytics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Cardlytics has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CDLX Dividends

 What is Cardlytics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Cardlytics dividends. Estimated to be 0% next year.
If you bought $2,000 of Cardlytics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Cardlytics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Cardlytics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:CDLX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
United States of America Media Industry Average Dividend Yield Market Cap Weighted Average of 28 Stocks 2%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 1948 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:CDLX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00
2019-11-14

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Cardlytics has not reported any payouts.
  • Unable to verify if Cardlytics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Cardlytics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Cardlytics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Cardlytics's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Cardlytics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Cardlytics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Cardlytics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CDLX Management

 What is the CEO of Cardlytics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Scott Grimes
COMPENSATION $2,148,965
AGE 56
TENURE AS CEO 11.4 years
CEO Bio

Mr. Scott D. Grimes has been Director of Westar Energy, Inc. since June 4, 2018. Mr. Grimes has been Senior Vice President of Risk and Operations at Wallaby Financial, Inc., since July 09, 2014. Mr. Grimes co-founded Cardlytics, Inc. in June, 2008 and also has been its Chief Executive Officer and Director since June, 2008. He serves as a Business Advisor of PowerLoom Corporation. Mr. Grimes serves as an Observer of Silicon Optix. He is a Risk Management Professional with over twenty years’ experience in fraud, AML and compliance functions. He previously served as Vice President, Risk Management at Green Dot Corporation from 2007 to 2013. Prior to joining Green Dot, he served in senior executive roles focused on risk and compliance at Target Corporation and Capital One Financial Corporation. He was Vice President of Strategy for Capital and General Manager of Payments for One Financial Corporation from 2003 to 2005. He served as Principal of Canaan Partners. Mr. Grimes joined Canaan in 2002. Mr. Grimes was Senior Vice President and General Manager, Payments at Capital One Financial Corporation and from 2003 to 2005, where he developed and launched decoupled debit. He served as Chief Executive Officer of PowerLoom Corporation. He served as Senior Vice President of Business Development for FreeMarkets, Inc., an e-sourcingcompany and a Principal at McKinsey & Company, a management consulting firm. As a Principal with McKinsey and Company, Mr. Grimes spent 8 years serving leading global organizations on M&A, marketing and technology issues. He began his career at Schlumberger Limited and held senior positions in engineering, marketing and general management during his 11 years with it. He served as Director of Great Plains Energy Incorporated. He has been a Director at Kansas City Power & Light Company and gmo since 2014. He is Independent Director of Evergy, Inc. since 2014. He served as a Director of Enpirion Inc. Mr. Grimes received an MBA from the Stanford Graduate School of Business and a BS in Electrical Engineering from Union College. He serves as Director at KCP&L Greater Missouri Operations Company.

CEO Compensation
  • Scott's compensation has increased whilst company is loss making.
  • Scott's remuneration is lower than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Cardlytics management team in years:

4
Average Tenure
49
Average Age
  • The tenure for the Cardlytics management team is about average.
Management Team

Scott Grimes

TITLE
Co-Founder
COMPENSATION
$2M
AGE
56
TENURE
11.4 yrs

Lynne Laube

TITLE
Co-Founder
COMPENSATION
$2M
AGE
49
TENURE
11.4 yrs

David Evans

TITLE
Chief Financial Officer
COMPENSATION
$2M
TENURE
3.1 yrs

Sathish Gaddipati

TITLE
Chief Technology Officer
AGE
52
TENURE
2.8 yrs

Kirk Somers

TITLE
Chief Legal & People Officer and Secretary
AGE
54
TENURE
5.3 yrs

Dani Cushion

TITLE
Chief Marketing Officer
AGE
41
TENURE
4.5 yrs

Dustin Renn

TITLE
Senior Vice President of Corporate Development
TENURE
0.3 yrs

Craig Snodgrass

TITLE
Chief Data Officer
AGE
46
TENURE
5.8 yrs

Megan McKean

TITLE
Senior Vice President of Advertiser Services
AGE
37
TENURE
3.5 yrs

Jared Luskin

TITLE
TENURE
0.8 yrs
Board of Directors Tenure

Average tenure and age of the Cardlytics board of directors in years:

8.2
Average Tenure
56
Average Age
  • The tenure for the Cardlytics board of directors is about average.
Board of Directors

John Balen

TITLE
Independent Chairman
COMPENSATION
$203K
AGE
56
TENURE
2.6 yrs

Scott Grimes

TITLE
Co-Founder
COMPENSATION
$2M
AGE
56
TENURE
11.4 yrs

Lynne Laube

TITLE
Co-Founder
COMPENSATION
$2M
AGE
49
TENURE
11.4 yrs

Mark Johnson

TITLE
Independent Director
COMPENSATION
$184K
AGE
66
TENURE
9.1 yrs

Dave Adams

TITLE
Independent Director
COMPENSATION
$283K
AGE
63
TENURE
8.2 yrs

Bryce Youngren

TITLE
Independent Director
COMPENSATION
$195K
TENURE
11.3 yrs

Tony Weisman

TITLE
Independent Director
COMPENSATION
$180K
AGE
59
TENURE
5.1 yrs

Jack Klinck

TITLE
Independent Director
COMPENSATION
$188K
AGE
55
TENURE
3.1 yrs

Aimée Lapic

TITLE
Independent Director
AGE
49
TENURE
0.6 yrs
Who owns this company?
Recent Insider Trading
  • Cardlytics individual insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
15. Oct 19 Buy CAS Investment Partners, LLC Company 11. Oct 19 14. Oct 19 68,252 $36.79 $2,510,527
11. Oct 19 Buy CAS Investment Partners, LLC Company 10. Oct 19 10. Oct 19 14,842 $34.67 $514,572
10. Oct 19 Buy CAS Investment Partners, LLC Company 08. Oct 19 09. Oct 19 73,578 $33.68 $2,454,133
09. Oct 19 Buy CAS Investment Partners, LLC Company 07. Oct 19 07. Oct 19 40,000 $33.32 $1,332,800
29. Oct 19 Buy CAS Investment Partners, LLC Company 22. Oct 19 23. Oct 19 80,926 $37.79 $3,018,666
23. Oct 19 Buy CAS Investment Partners, LLC Company 21. Oct 19 21. Oct 19 28,123 $37.87 $1,065,018
22. Oct 19 Buy CAS Investment Partners, LLC Company 18. Oct 19 18. Oct 19 16,106 $37.62 $605,908
17. Oct 19 Buy CAS Investment Partners, LLC Company 15. Oct 19 16. Oct 19 9,490 $37.63 $356,689
13. Sep 19 Sell Lynne Laube Individual 13. Sep 19 13. Sep 19 -200,000 $32.30 $-6,460,000
13. Sep 19 Sell TTV Capital Company 13. Sep 19 13. Sep 19 -100,000 $32.30 $-3,230,000
13. Sep 19 Sell Scott Grimes Individual 13. Sep 19 13. Sep 19 -250,000 $32.30 $-8,075,000
28. Aug 19 Sell Air Canada Company 26. Aug 19 26. Aug 19 -1,500,000 $29.95 $-44,925,000
28. Aug 19 Sell Polaris Partners Company 26. Aug 19 27. Aug 19 -135,000 $36.09 $-4,723,039
23. Aug 19 Sell Polaris Partners Company 21. Aug 19 23. Aug 19 -94,796 $33.34 $-3,154,680
20. Aug 19 Sell Polaris Partners Company 16. Aug 19 20. Aug 19 -64,786 $34.27 $-2,216,085
15. Aug 19 Sell Polaris Partners Company 14. Aug 19 14. Aug 19 -465 $32.56 $-15,141
15. Aug 19 Sell Polaris Partners Company 13. Aug 19 14. Aug 19 -174,230 $34.10 $-5,872,536
13. Aug 19 Sell Canaan Partners Company 12. Aug 19 12. Aug 19 -187,683 $33.11 $-5,991,633
13. Aug 19 Sell Tony Weisman Individual 12. Aug 19 12. Aug 19 -8,484 $31.36 $-266,058
22. Jul 19 Sell Polaris Partners Company 18. Jul 19 18. Jul 19 -589 $27.87 $-16,414
11. Jun 19 Sell Polaris Partners Company 07. Jun 19 07. Jun 19 -100,000 $25.62 $-2,562,120
07. Jun 19 Sell Polaris Partners Company 04. Jun 19 06. Jun 19 -75,284 $25.30 $-1,814,073
31. May 19 Sell Polaris Partners Company 28. May 19 28. May 19 -100,000 $23.04 $-2,303,810
X
Management checks
We assess Cardlytics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Cardlytics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CDLX News

Simply Wall St News

Director Tony Weisman Just Sold A Bunch Of Shares In Cardlytics, Inc. (NASDAQ:CDLX)

See our latest analysis for Cardlytics The Last 12 Months Of Insider Transactions At Cardlytics In fact, the recent sale by Tony Weisman was the biggest sale of Cardlytics shares made by an insider individual in the last twelve months, according to our records. … While insider selling is not a positive sign, we can't be sure if it does mean insiders think the shares are fully valued, so it's only a weak sign. … NasdaqGM:CDLX Recent Insider Trading, August 15th 2019 Insider Ownership Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own.

Simply Wall St -

When Will Cardlytics, Inc. (NASDAQ:CDLX) Become Profitable?

See our latest analysis for Cardlytics CDLX is bordering on breakeven, according to the 7 Media analysts. … NasdaqGM:CDLX Past and Future Earnings, August 13th 2019 Underlying developments driving CDLX’s growth isn’t the focus of this broad overview, but, take into account that generally a high forecast growth rate is not unusual for a company that is currently undergoing an investment period. … Next Steps: This article is not intended to be a comprehensive analysis on CDLX, so if you are interested in understanding the company at a deeper level, take a look at CDLX’s company page on Simply Wall St.

Simply Wall St -

Does Cardlytics (NASDAQ:CDLX) Have A Healthy Balance Sheet?

NasdaqGM:CDLX Historical Debt, July 3rd 2019 How Healthy Is Cardlytics's Balance Sheet? … So while it's hard to imagine that the US$672.3m company is struggling for cash, we still think it's worth monitoring its balance sheet. … Either way, since Cardlytics does have more debt than cash, it's worth keeping an eye on its balance sheet.

Simply Wall St -

Update: Cardlytics (NASDAQ:CDLX) Stock Gained 11% In The Last Year

(NASDAQ:CDLX) share price is up 11% in the last year, clearly besting than the market return of around 1.5% (not including dividends). … Check out our latest analysis for Cardlytics Cardlytics isn't a profitable company, so it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). … Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip.

Simply Wall St -

Will Cardlytics, Inc.'s (NASDAQ:CDLX) Earnings Grow Over The Next Few Years?

(NASDAQ:CDLX) released its most recent earnings announcement, which … that losses became smaller relative to the prior year's level … as a result of recent tailwinds

Simply Wall St -

Cardlytics, Inc. (NASDAQ:CDLX): Time For A Financial Health Check

(NASDAQ:CDLX) with its market cap of US$372m, are popular for their explosive growth, investors should also be aware of their balance sheet to judge whether the company can survive a downturn.

Simply Wall St -

Can We See Significant Insider Ownership On The Cardlytics Inc (NASDAQ:CDLX) Share Register?

A look at the shareholders of Cardlytics Inc (NASDAQ:CDLX) can tell us which group is most powerful. … Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Cardlytics is not a large company by global standards.

Simply Wall St -

Have You Considered This Before Investing In Cardlytics Inc (NASDAQ:CDLX)?

If you are currently a shareholder in Cardlytics Inc (NASDAQ:CDLX), or considering investing in the stock, you need to examine how the business generates cash, and how it is reinvested. … What is left after investment, determines the value of the stock since this cash flow technically belongs to investors of the company. … Cardlytics generates cash through its day-to-day business, which needs to be reinvested into the company in order for it to continue operating.

Simply Wall St -

Are Cardlytics Inc's (NASDAQ:CDLX) Interest Costs Too High?

Investors are always looking for growth in small-cap stocks like Cardlytics Inc (NASDAQ:CDLX), with a market cap of US$390.69m. … However, an important fact which most ignore is: how financially healthy is the business?

Simply Wall St -

Want To Invest In Cardlytics Inc (NASDAQ:CDLX)? Here's How It Performed Lately

Today I will assess CDLX's recent performance announced on 31 March 2018 and evaluate these figures to its longer term trend and industry movements. … How Did CDLX's Recent Performance Stack Up Against Its Past. … CDLX is loss-making, with the most recent trailing twelve-month earnings of -US$32.89m (from 31 March 2018), which compared to last year has become.

Simply Wall St -

CDLX Company Info

Description

Cardlytics, Inc. operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company’s platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. It also provides solutions that enable marketers and marketing service providers to leverage the power of purchase intelligence outside the banking channel. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Details
Name: Cardlytics, Inc.
CDLX
Exchange: NasdaqGM
Founded: 2008
$1,464,024,938
25,711,713
Website: http://www.cardlytics.com
Address: Cardlytics, Inc.
675 Ponce de Leon Avenue NE,
Suite 6000,
Atlanta,
Georgia, 30308,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM CDLX Common Stock Nasdaq Global Market US USD 09. Feb 2018
DB CYX Common Stock Deutsche Boerse AG DE EUR 09. Feb 2018
Number of employees
Current staff
Staff numbers
421
Cardlytics employees.
Industry
Advertising
Media
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/14 00:37
End of day share price update: 2019/11/13 00:00
Last estimates confirmation: 2019/11/13
Last earnings filing: 2019/11/12
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.